Hormone Therapy Continuation in Women > 65 Years

1. Indications for Continuing Systemic Hormone Therapy After Age 65

• Women who started hormone therapy (HT) before age 60 or within 10 years of menopause and who have persistent, bothersome vasomotor symptoms (VMS) have a favorable benefit‑risk profile and may continue HT with individualized risk assessment. Endocrine Society 1
• Continuation is reasonable when the woman has low baseline cardiovascular risk (no prior myocardial infarction, stroke, or high‑risk profile). Endocrine Society 3
• Continuation is appropriate in women with low risk of venous thromboembolism (VTE). Endocrine Society 3
• Women with no history of breast cancer or other hormone‑sensitive malignancies may be considered for continuation. Endocrine Society 3
• HT may be continued when it is used to treat osteoporosis and alternative agents (bisphosphonates, denosumab) are unsuitable. Endocrine Society 3

2. Situations Where Initiation or Continuation Is Discouraged

• Initiating systemic HT at age ≥ 65 is generally not recommended because late initiation is associated with markedly increased hazards of any cancer (HR ≈ 2.2) and cerebrovascular events (HR ≈ 2.7). American College of Physicians (high‑quality cohort evidence) 2
• When a woman is > 10 years from menopause or older than 60, the absolute risks of coronary heart disease, stroke, VTE, and dementia rise, making the benefit‑risk ratio less favorable. American College of Physicians 2
• Systemic HT should not be started for chronic disease prevention (osteoporosis, cardiovascular disease) in women > 65; non‑hormonal alternatives are preferred. American College of Physicians 9
• Oral estrogen formulations should be avoided in favor of transdermal or vaginal routes because oral preparations carry higher thrombotic risk. Endocrine Society (expert consensus) 2

3. Preferred Formulations and Dosing

• Transdermal (or vaginal) estrogen is strongly preferred over oral estrogen for women continuing HT after 65 because it bypasses first‑pass hepatic metabolism, reducing VTE and stroke risk. Endocrine Society 2
• Estradiol‑based products are favored over conjugated equine estrogens due to a more favorable thrombotic and metabolic safety profile. Endocrine Society (expert consensus)
• Lowest effective dose should be used to control symptoms; low‑dose regimens have demonstrated greater risk reduction compared with medium or high doses in senior Medicare women. American College of Physicians (moderate evidence) [5][6]7

4. Monitoring and Periodic Reassessment

• Perform annual reassessment of VMS severity and persistence. Endocrine Society 1
• Re‑evaluate cardiovascular risk factors (blood pressure, lipids, diabetes status, new events) each year. American College of Physicians 2
• Conduct breast‑cancer screening per standard guidelines and reassess individual breast‑cancer risk annually. American College of Physicians 2
• Screen for new contraindications (new VTE, stroke, myocardial infarction, breast‑cancer diagnosis) at each visit. Endocrine Society 1
• If HT was prescribed for bone health, repeat bone‑density assessment as indicated. Endocrine Society 3

5. Management of Isolated Genitourinary Syndrome of Menopause

• For women with only genitourinary symptoms, low‑dose vaginal estrogen is the preferred therapy; it provides minimal systemic absorption and does not increase cardiovascular or breast‑cancer risk. American Society of Clinical Oncology 8

6. Non‑Hormonal Alternatives When HT Must Be Discontinued

All recommendations are based on cited peer‑reviewed evidence and reflect the strength of evidence where reported (high‑quality cohort data, moderate‑level randomized or observational studies, or expert consensus).